Choosing new therapies for gonorrhoea: we need to consider the impact on the pan-Neisseria genome: a viewpoint

Chris Kenyon; Jolein Laumen; Sheeba Manoharan-Basil

doi:10.3390/antibiotics10050515

Choosing new therapies for gonorrhoea: we need to consider the impact on the pan-Neisseria genome: a viewpoint

Chris Kenyon, Jolein Laumen, Sheeba Manoharan-Basil

Sexually Transmitted Infections

Research output: Contribution to journal › A1: Web of Science-article › peer-review

16 Downloads (Pure)

Abstract

The development of new gonorrhoea treatment guidelines typically considers the resistance-inducing effect of the treatment only on Neisseria gonorrhoeae. Antimicrobial resistance in N. gonorrhoeae has, however, frequently first emerged in commensal Neisseria species and then been passed on to N. gonorrhoeae via transformation. This creates the rationale for considering the effect of gonococcal therapies on resistance in commensal Neisseria. We illustrate the benefits of this pan-Neisseria strategy by evaluating three contemporary treatment options for N. gonorrhoeae-ceftriaxone plus azithromycin, monotherapy with ceftriaxone and zoliflodacin.

Original language	English
Article number	515
Journal	Antibiotics-Basel
Volume	10
Issue number	5
Number of pages	12
ISSN	2079-6382
DOIs	https://doi.org/10.3390/antibiotics10050515
Publication status	Published - 2021

Keywords

N
gonorrrhoeae
Neisseria
antimicrobial resistance
antimicrobial consumption
dual therapy
ANTIMICROBIAL RESISTANCE
EUROPEAN GUIDELINE
EPIDEMIOLOGY
AZITHROMYCIN
MACROLIDE

Access to Document

10.3390/antibiotics10050515Licence: CC BY

2021anti0515Final published version, 1.52 MBLicence: CC BY

Cite this

@article{d17bfdc20e884c42ba09afaca60fc592,

title = "Choosing new therapies for gonorrhoea: we need to consider the impact on the pan-Neisseria genome: a viewpoint",

abstract = "The development of new gonorrhoea treatment guidelines typically considers the resistance-inducing effect of the treatment only on Neisseria gonorrhoeae. Antimicrobial resistance in N. gonorrhoeae has, however, frequently first emerged in commensal Neisseria species and then been passed on to N. gonorrhoeae via transformation. This creates the rationale for considering the effect of gonococcal therapies on resistance in commensal Neisseria. We illustrate the benefits of this pan-Neisseria strategy by evaluating three contemporary treatment options for N. gonorrhoeae-ceftriaxone plus azithromycin, monotherapy with ceftriaxone and zoliflodacin.",

keywords = "N, gonorrrhoeae, Neisseria, antimicrobial resistance, antimicrobial consumption, dual therapy, ANTIMICROBIAL RESISTANCE, EUROPEAN GUIDELINE, EPIDEMIOLOGY, AZITHROMYCIN, MACROLIDE",

author = "Chris Kenyon and Jolein Laumen and Sheeba Manoharan-Basil",

note = "FTX; DOAJ; (CC BY 4.0)",

year = "2021",

doi = "10.3390/antibiotics10050515",

language = "English",

volume = "10",

journal = "Antibiotics-Basel",

issn = "2079-6382",

publisher = "MDPI AG",

number = "5",

}

TY - JOUR

T1 - Choosing new therapies for gonorrhoea: we need to consider the impact on the pan-Neisseria genome: a viewpoint

AU - Kenyon, Chris

AU - Laumen, Jolein

AU - Manoharan-Basil, Sheeba

N1 - FTX; DOAJ; (CC BY 4.0)

PY - 2021

Y1 - 2021

N2 - The development of new gonorrhoea treatment guidelines typically considers the resistance-inducing effect of the treatment only on Neisseria gonorrhoeae. Antimicrobial resistance in N. gonorrhoeae has, however, frequently first emerged in commensal Neisseria species and then been passed on to N. gonorrhoeae via transformation. This creates the rationale for considering the effect of gonococcal therapies on resistance in commensal Neisseria. We illustrate the benefits of this pan-Neisseria strategy by evaluating three contemporary treatment options for N. gonorrhoeae-ceftriaxone plus azithromycin, monotherapy with ceftriaxone and zoliflodacin.

AB - The development of new gonorrhoea treatment guidelines typically considers the resistance-inducing effect of the treatment only on Neisseria gonorrhoeae. Antimicrobial resistance in N. gonorrhoeae has, however, frequently first emerged in commensal Neisseria species and then been passed on to N. gonorrhoeae via transformation. This creates the rationale for considering the effect of gonococcal therapies on resistance in commensal Neisseria. We illustrate the benefits of this pan-Neisseria strategy by evaluating three contemporary treatment options for N. gonorrhoeae-ceftriaxone plus azithromycin, monotherapy with ceftriaxone and zoliflodacin.

KW - N

KW - gonorrrhoeae

KW - Neisseria

KW - antimicrobial resistance

KW - antimicrobial consumption

KW - dual therapy

KW - ANTIMICROBIAL RESISTANCE

KW - EUROPEAN GUIDELINE

KW - EPIDEMIOLOGY

KW - AZITHROMYCIN

KW - MACROLIDE

U2 - 10.3390/antibiotics10050515

DO - 10.3390/antibiotics10050515

M3 - A1: Web of Science-article

SN - 2079-6382

VL - 10

JO - Antibiotics-Basel

JF - Antibiotics-Basel

IS - 5

M1 - 515

ER -

Choosing new therapies for gonorrhoea: we need to consider the impact on the pan-Neisseria genome: a viewpoint

Abstract

Keywords

Access to Document

Fingerprint

Cite this